Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27784
Under the amended Agreement, licensor assigned to licensee rights in the patents claiming the composition and therapeutic methods of using OGX-011 and granted licensee a worldwide, nonexclusive License to know-how and patents covering core antisense technology and manufacturing technology solely for use with OGX-011. The key product-related patent that was assigned to licensee was U.S. Patent number 6,900,187 having an expiration date of at least 2020; and the key core antisense technology patents that were Licensed are U.S. Patent number 7,919,472 having an expiration date of 2026 and its foreign equivalents pending in Australia, Canada, the European Patent Convention and Japan.
In December 2009, licensee granted sublicensee the exclusive worldwide right and License to develop and commercialize any products containing OGX-011 and related compounds, with licensee having an option to co-promote OGX-011 in the United States and Canada.
In January 2005, licensor entered into a further Agreement with OncoGenex to allow for the development of an additional second-generation antisense anti-cancer drug. In April 2005, licensee selected OGX-427 to develop under the collaboration.
IPSCIO Record ID: 27866
Update: in December 2009 the Licensee entered into a global licensing and partnership agreement with a third company. The Licensor in the transaction above continues to receive payments from the secondary License too.
IPSCIO Record ID: 203444
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan, to conduct the Licensor Clinical Studies, subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.
The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.
Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as
permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to: Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.
The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.